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Abstract
Background: Preeclampsia and intrauterine fetal growth restriction (IUGR) are two of the most common causes
of maternal and perinatal morbidity and mortality. Current methods of predicting those at most risk of these
conditions remain relatively poor, and in clinical practice past obstetric history remains the most commonly used
tool. Aspirin and, in women at risk of preeclampsia only, calcium have been demonstrated to have a modest effect
on risk reduction. Several observational studies and randomised trials suggest that low molecular weight heparin
(LMWH) therapy may confer some benefit.
Methods/design: This is a multicentre open label randomised controlled trial to determine the effect of the
LMWH, enoxaparin, on the prevention of recurrence of preeclampsia and/or IUGR in women at high risk due to
their past obstetric history in addition to standard high risk care for all participants.
Inclusion criteria: A singleton pregnancy >6+0 and <16+0 weeks gestation with most recent prior pregnancy with
duration >12 weeks having; (1) preeclampsia delivered <36+0 weeks, (2) Small for gestational age (SGA) infant <10th
customised birthweight centile delivered <36+0 weeks or, (3) SGA infant ≤3rd customised birthweight centile
delivered at any gestation. Randomisation is stratified for maternal thrombophilia status and women are randomly
assigned to ‘standard high risk care’ or ‘standard high risk care’ plus enoxaparin 40 mg from recruitment until 36+0
weeks or delivery, whichever occurs sooner. Standard high risk care includes the use of aspirin 100 mg daily and
calcium 1000–1500 mg daily (unless only had previous SGA with no preeclampsia).
The primary outcome is preeclampsia and/or SGA <5th customised birthweight centile. Analysis will be by intention
to treat.
Discussion: The EPPI trial has more focussed and clinically relevant inclusion criteria than other randomised trials
with a more restricted composite primary outcome. The inclusion of standard use of aspirin (and calcium) for all
participants will help to ensure that any differences observed in outcome are likely to be related to enoxaparin use.
These data will make a significant contribution to future meta-analyses and systematic reviews on the use of LMWH
for the prevention of placental mediated conditions.
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Background
Preeclampsia and intrauterine fetal growth restriction
(IUGR) are two of the most common causes of maternal
and perinatal morbidity and mortality. Preeclampsia
complicates approximately 3–5% of pregnancies and re-
mains one of the most common causes of direct mater-
nal death in the developed world [1]. IUGR is more
difficult to define and measure but approximately 10% of
all infants will be born small for gestational (SGA) de-
fined as birthweight < 10th customised birthweight cen-
tile and at least two thirds of these have evidence of
abnormal uterine and umbilical Doppler waveforms if
diagnosed prior to birth suggesting significant utero-
placental disease and fetal growth restriction [2]. Infants
who are born growth restricted with or without maternal
preeclampsia are at increased risk of morbidity and mor-
tality during the perinatal period [3–5], and this risk
continues into childhood and adult life with higher rates
of neurosensory disability, cognitive impairment, short
stature, hypertension, diabetes and long term cardiovas-
cular disease [6–11]. Women with preeclampsia and/or
IUGR fetuses are more likely to require preterm delivery,
with over one third of women with preeclampsia and
15% of SGA infants delivering <37 weeks [12]. Iatrogenic
preterm birth often results in operative delivery and
therefore has inherent risks to the mother and results in
the significant additional risks of prematurity for an
already compromised infant [3, 13–15].
There are a wide variety of identified risk factors for
preeclampsia and/or IUGR but few contribute signifi-
cantly to risk prediction models which at best remain
modest [16, 17]. Until relatively recently it has been sug-
gested that inherited thrombophilias are associated with
preeclampsia and IUGR, however, more recent evidence
from prospective cohort studies suggests this associ-
ation, if present, is only weak [18]. Past obstetric history
is the most commonly used method for risk assessment
in current clinical practice. Women who have had
previous preeclampsia and/or IUGR are at significant
risk of recurrence especially when the disease oc-
curred early in the previous pregnancy with rates ran-
ging from 15 to 47% depending on the severity of
previous disease [19–22].
Both conditions are considered placental diseases and
there are likely synergies in pathological mechanisms
which may present as a maternal syndrome (preeclampsia
only), a fetal syndrome (IUGR only) or a combined clinical
syndrome (preeclampsia and IUGR) depending on fetal
and maternal responses to the pathological process. The
synergies in the pathological mechanisms have led many
investigators to research common therapeutic and pre-
ventative strategies for both diseases. Aspirin and calcium
have been trialled in a large number of randomised studies
in a variety of populations and although effect sizes are
modest both significantly reduce the incidence of pre-
eclampsia [23], and aspirin also decreases the incidence of
SGA [24]. They should be considered as standard practice
in women at high risk of these conditions [25].
Heparin and low molecular weight heparin (LMWH)
have also been proposed as potential preventative ther-
apies for a number of placental mediated pregnancy
complications including preeclampsia and IUGR. Their
effect may relate to their anticoagulant effect although it
is also likely that additional effects on trophoblast devel-
opment may be more significant [26–28]. Initial interest
in the use of heparin for the prevention of placental
mediated complications centred on the treatment of re-
current miscarriage associated with anti-phospholipid
syndrome (APS). Early studies demonstrated significant
benefit of unfractionated heparin with aspirin when
compared to aspirin alone [29, 30]. This led many clini-
cians to routinely treat these women with LMWH for all
pregnancy complications associated with APS and this
practice has continued despite subsequent studies failing
to demonstrate the same improvements in pregnancy
outcomes with LMWH and aspirin [31, 32].
Some clinicians extended their use of heparin and
LMWH for the prevention of preeclampsia and IUGR to
women regarded at high risk of these complications for
other reasons, such as those with renal disease [33],
women with ACE DD polymorphism [34] and women
with inherited thrombophilia [35, 36]. These small ob-
servational and non-placebo controlled trials suggested
significant benefits associated with heparin and LMWH.
Subsequently a number of randomised controlled trials
have been reported. Initial trials focussed specifically on
populations with or without thrombophilia, believing
that the risk of these placental diseases may be signifi-
cantly different between the groups and may respond
differently to intervention with heparin or LMWH. In
2009, Rey et al. reported the outcomes of a randomised
trial of LMWH in women with a past history of
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placental mediated problems (including preeclampsia
and IUGR) and no thrombophilia. This trial demon-
strated a large reduction in the primary composite out-
come (severe preeclampsia, birthweight <5th centile,
major abruption or fetal death after 20 weeks) 5.5 vs
23.6% adjOR 0.15, 95% CI 0.03–0.70 [37]. However the
study was halted after just over one third of the planned
participants had been recruited (results of 110 partici-
pants analysed of a planned sample size of 276 women).
The FRUIT-RCT reported similar promising outcomes
associated with LMWH use for women with inherited
thrombophilia, demonstrating a significant reduction in
the recurrence of hypertensive disease (preeclampsia,
HELLP syndrome and/or eclampsia) <34 weeks gesta-
tion, 8.7 vs 0% risk difference 8.7, 95% CI 1.9–15.5%)
[38]. This study also did not complete recruitment of
initial planned sample size (139 of 262).
Subsequent published trials including the ‘Heparin in
pregnant women with adverse pregnancy outcome to im-
prove rate of successful pregnancy’ (HAPPY) Study [39],
the ‘Prevention of maternal and perinatal complications
by enoxaparin in women with previous severe preeclamp-
sia’ (HEPEPE) Study [40] and the ‘Thrombophilia in Preg-
nancy Prophylaxis Study’ (TIPPS Study) [41] have failed to
demonstrate any improvement in outcome with LMWH.
All of these trials have had prolonged recruitment
phases (up to 12 years [41]) and have been difficult to
recruit to. Several trials have stopped early due to re-
cruitment difficulties and for perceived overwhelming ef-
fect [37] or futility after interim data analysis [39]. Of
note, these previous randomised controlled trials have
had broad inclusion criteria and diverse composite out-
come measures.
The EPPI trial aims to be more precise, and clinically
relevant, with its inclusion criteria and primary outcome
measures specific to women at high risk of preeclampsia
and/or IUGR. Account will be made of each participant’s
thrombophilia status but this will not define the study
population. Standard high risk care will include the
use of aspirin and, where appropriate, calcium for all
women. This is the first trial in this setting to also in-




To assess the effectiveness of LMWH, enoxaparin 40 mg
daily, for the prevention of recurrence of preeclampsia
and IUGR regardless of thrombophilia status and in
addition to standard high risk antenatal care (including
the use of aspirin and, where appropriate calcium).
Study design
A multicentre open label randomised controlled trial.
Study setting
The trial will recruit women from high risk clinic settings
in New Zealand at National Women’s Health, Auckland
City Hospital; in Australia at the Royal Women’s Hospital,
Melbourne, the Mercy Hospital for Women, Melbourne
and the Sunshine Hospital, Melbourne; and in the
Netherlands at the Academic Medical Centre, Amsterdam.
Inclusion criteria
Women are eligible for the trial if they are >6+0 and <16+0
weeks gestation with fetal viability and a singleton preg-
nancy confirmed on ultrasound scan and at risk of pre-
eclampsia and/or IUGR based on their past obstetric
history. This is defined by (1) previous preeclampsia de-
livered <36+0 weeks in their last on-going pregnancy
reaching >12 weeks, (2) previous SGA < 10th custo-
mised birthweight centile delivered <36+0 weeks in their
last ongoing pregnancy reaching >12 weeks with no
major fetal anomaly or, (3) previous SGA ≤ 3rd custo-
mised birthweight centile delivered at any gestation in
their last on-going pregnancy reaching >12 weeks with
no major fetal anomaly.
Exclusion criteria
Women are not eligible for the trial if they have (1) any
contraindication to LMWH use, (2) a requirement for
LMWH use such as previous thrombosis, APS, (3) previ-
ous successful pregnancy with LMWH treatment, (4)
multiple pregnancy, (5) known pre-existing type 1 or 2
diabetes or renal disease (with serum creatinine >150),
(6) thrombocytopenia (platelet count <80 × 109/L) prior
to randomisation or (7) a known major fetal anomaly/
chromosomal abnormality.
Trial entry and informed consent
All eligible women will be invited to participate in the
study. Trial information will be provided verbally and by
a written information sheet by clinicians caring for
women and research midwives. Eligible women will be
encouraged to take time to consider involvement in the
study and to discuss participation with their partners
and/or family prior to providing written consent. For
women who decline to participate in the trial, antenatal
care relevant to their risk factors will be offered, the use
of LMWH will not be offered as part of standard care.
All trial participants will be free to withdraw from the
study at any time if they so wish, appropriate on-going
antenatal care will be arranged according to clinical risk.
Randomisation
A computer generated randomisation programme will
be used with stratification for recruiting site and inher-
ited thrombophilia status to ensure equal distribution
across study groups. Women who have been tested prior
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to trial involvement will be assigned to (i) positive
thrombophilia or (ii) negative thrombophilia. For women
not tested or partially tested (with negative result), sam-
ples will be taken before any use of LMWH and tested for
antithrombin deficiency, protein C deficiency, protein S
deficiency, factor V Leiden, and the prothrombin gene
mutation. Results will not be revealed to participant, clini-
cians or investigators until the study is completed. These
women will be assigned to (iii) unknown thrombophilia
status. Randomisation will be in blocks of five.
All participants will be assigned a sequential study
identifying number (ID) according to thrombophilia sta-
tus. At the lead recruiting site (National Women’s
Health, Auckland City Hospital) randomisation will
occur by telephone to the hospital pharmacy clinical tri-
als service and study group allocation made by study ID.
In all other sites sequential sealed opaque envelopes for
each study ID will be opened to reveal study group.
Study groups
Women will be assigned to one of two groups; Group
one will receive ‘standard high risk care’ and Group two
will receive ‘standard high risk care’ and enoxaparin
40 mg sc (Clexane®, Sanofi-Aventis) [42] daily from re-
cruitment (at gestational age >6+0 and <16+0 weeks)
until 36+0 weeks or delivery, whichever occurs sooner.
Standard high risk care is defined as care co-ordinated
by a high risk antenatal clinic service, aspirin 100 mg
daily until 36+0 weeks and calcium 1000–1500 mg daily
until 36+0 weeks (unless only had previous SGA with no
preeclampsia as eligibility criteria). This is an open-label
randomised study and all participants, clinicians and
investigators will be aware of study group assignment.
Obstetric care and trial procedure (Fig. 1)
All women will have serum samples taken at recruit-
ment, 20 and 30 weeks gestation. Samples will be centri-
fuged and stored in −80 °C freezer for later assessment
of placental and angiogenic growth factors (Table 1). At
the time of fetal anatomy scan, standard fetal growth
parameters [43, 44] and uterine and umbilical arterial
Doppler waveforms [45] will be recorded. These ultra-
sound measurements will be repeated at 24 weeks’ gesta-
tion. Data from any additional antenatal ultrasound scans
will also be collected.
For women receiving LMWH, an educational session
regarding injection technique will be provided by a re-
search midwife prior to treatment commencement.
LMWH injections will be re-supplied on a monthly basis
from hospital pharmacies. Treatment will continue until
36+0 weeks but additional safety indications to stop
treatment sooner include; need for delivery prior to 36+0
weeks (stop once decision made for delivery or 12 h
prior to induction of labour or elective caesarean section,
whichever is later), episode of threatened preterm labour
(treatment can be recommenced if symptoms settle), clin-
ical evidence of placental abruption or thrombocytopenia
with platelet count <80 × 109/L.
Antenatal, intra-partum and postnatal care will be pro-
vided by the local obstetric team caring for each woman.
Pregnancy, labour, postnatal and neonatal data will be
collected by research staff from maternal and infant
clinical records up to the time of hospital discharge.
Study outcomes
The primary outcome is the incidence of preeclampsia
and/or small for gestational age (SGA) <5th customised
birthweight centile [46]. Preeclampsia will be defined as
new onset hypertension (systolic BP ≥140 mmHg and/or
diastolic BP ≥90 mmHg) arising after 20 weeks gestation
with evidence of significant proteinuria (dipstick protein-
uria (≥1+) subsequently confirmed by spot urine pro-
tein/creatinine ratio ≥ 30 mg/mmol and/or 24 h urine
protein excretion >0.3 g) or any multi-system complica-
tion including haematological, liver, renal and neuro-
logical involvement [47]. IUGR is difficult to define and
measure and so SGA defined by customised birthweight
centiles will be used as the most reproducible surrogate.
Fig. 1 Individual participant trial schedule
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Customised centiles adjusting for infant sex, gestation at
delivery and maternal variables—parity, ethnicity, height
and weight will be used [46]. The key secondary study
outcomes are shown in Table 1.
Sample size
We have estimated a risk of recurrence of preeclampsia
and/or SGA < 5th customised centile for the included
population of 25% when managed routinely with aspirin
(and calcium). A trial of 160 participants, allowing for a
5% drop-out/early miscarriage rate will have 80% power
at a two-sided significance level of 0.05 to detect a differ-
ence between 25 and 7% [37].
Data monitoring committee (DMC) and interim analysis
An independent DMC comprising of a statistician, ob-
stetrician, and obstetric physician with clinical trials ex-
perience will review serious adverse events. They will
review the results of an interim analysis once 98 partici-
pants have been recruited and completed pregnancy. A
study group of 49 participants in each arm will have 80%
power at a two-sided significance level of 0.05 to detect
a difference between 25 and 4%. The DMC will report to
the trial investigator group and may advise discontinu-
ation of the trial if there is an excess of serious adverse
events in the LMWH treatment group or if a significant
benefit is already demonstrated. Results of the interim
analysis will only be known to members of the DMC
and the trial investigator group. Responsibility for early
discontinuation of the trial will ultimately rest with the
trial investigator group.
Data analysis
All data will be collected and stored under de-identified
study ID. Data will be analysed by an independent statis-
tician. Population characteristics between the groups will
be compared initially to identify any potential confound-
ing variables. Data will be analysed on an intention to
treat basis comparing primary and secondary outcomes
in both groups. Analyses will make adjustment for
recruiting site and thrombophilia status. P-value <0.05
will be considered significant.
Discussion
This is a protocol for a randomised trial to assess the
role of the LMWH, enoxaparin, to prevent recurrence of
preeclampsia and IUGR in women at high risk based on
their past obstetric history. The EPPI trial has been de-
signed to focus specifically on the related conditions of
preeclampsia and IUGR. The inclusion criteria aim to
identify women with or without thrombophilia but do
not include less specific or poorly defined conditions
such as past venous thromboembolism, recurrent mis-
carriage, unexplained fetal death and placental abruption
as seen in some other trials of heparin therapy for the
prevention of preeclampsia and IUGR. The pathological
mechanisms of such a wide variety of conditions are
likely to be significantly different from those of pre-
eclampsia and IUGR and a single preventative therapy
less likely to be effective for all. Similarly the composite
primary outcome measure for this study has been lim-
ited to preeclampsia and a measure of IUGR (SGA) so
results are more likely to be relevant to these placental
mediated conditions.
Another strength of this study is that both treatment
arms will receive standard high risk care including the
use of aspirin in all women and, for those with previous
history of preeclampsia, the use of calcium. Any differ-
ences observed in outcome are likely to be related to
enoxaparin use.
This study will include 160 women and is one of the
larger studies in this area. The findings of this trial will
be available for future meta-analysis and systematic re-
views. It will significantly contribute to and further
current knowledge regarding the use enoxaparin in preg-
nancy to reduce recurrence of preeclampsia and IUGR.
Table 1 EPPI trial key secondary study outcomes
Combined Preeclampsia and/or SGA <10th centile
Preeclampsia and/or SGA <10th centile
delivered <35+6 weeks
Preeclampsia and/or SGA <10th centile
delivered <33+6 weeks
Preeclampsia and SGA <10th centile








Infant SGA <10th centile
SGA <5th centile
SGA <3rd centile
Unexplained intrauterine fetal death
Stillbirth
Gestational age at delivery
Mean birthweight
Mean birthweight centile
Neonatal Intensive Care Unit admission
Neonatal death
Uteroplacental Abnormal uterine artery Doppler
waveform at 20 or 24 weeks
Abnormal umbilical artery Doppler
waveform at 20 or 24 weeks
Placental & angiogenic growth
factors
soluble fms-like tyrosine kinase-1 (sFlt-1)
soluble endoglin (soluble Eng)
Endothelin-1 (ET-1)
Placental growth factor (PLGF)
soluble vascular cell adhesion molecule
1 (VCAM1)
SGA small for gestational age, all SGA measured by customised birthweight
centile [46]
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